Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8476 to 8490 of 9025 results

  1. Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [ID6738]

    In development Reference number: GID-TA11913 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)

    This guidance has been updated and replaced by NICE's technology appraisal guidance on sodium zirconium cyclosilicate for treating hyperkalaemia (TA1148).

    Withdrawn guidance

  3. Nivolumab monotherapy for non-small-cell lung cancer [ID1088]

    Discontinued Reference number: GID-TA10148

    Technology appraisal guidance
    Discontinued

  4. Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments (TA881)

    This guidance has been updated and replaced by NICE technology appraisal guidance on ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors (TA1146).

    Withdrawn guidance

  5. Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]

    In development Reference number: GID-TA11137 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]

    In development Reference number: GID-TA11303 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651]

    In development Reference number: GID-TA11863 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Ligelizumab for previously treated chronic spontaneous urticaria in people 12 years and over [ID3999]

    Discontinued Reference number: GID-TA10891

    Technology appraisal guidance
    Discontinued

  9. Baricitinib for treating active autoantibody-positive systemic lupus erythematosus [ID3997]

    Discontinued Reference number: GID-TA10892

    Technology appraisal guidance
    Discontinued

  10. Non-invasive skin closure devices for surgical incisions (MT775)

    In development Reference number: GID-MT593 Expected publication date: TBC

    Medical technologies guidance
    In development

  11. Surgical vessel sealing systems (MT798)

    In development Reference number: GID-MT594 Expected publication date: TBC

    Medical technologies guidance
    In development

  12. Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111]

    Discontinued Reference number: GID-TA10306

    Technology appraisal guidance
    Discontinued

  13. Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery [ID1149]

    Discontinued Reference number: GID-TA10297

    Technology appraisal guidance
    Discontinued

  14. Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

    Discontinued Reference number: GID-TA10566

    Technology appraisal guidance
    Discontinued

  15. Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]

    Discontinued Reference number: GID-TA10390

    Technology appraisal guidance
    Discontinued